Esperion Therapeutics Inc. has announced the commencement of an underwritten public offering of shares of its common stock. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. All shares in the proposed offering will be sold by Esperion. Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers. The offering is being conducted pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. Final terms will be disclosed in a prospectus supplement to be filed with the SEC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541765-en) on October 07, 2025, and is solely responsible for the information contained therein.